Please enable JavaScript to continue using this application.

Compare $IKT vs $VNDA | Chartloom

Compare

$IKT vs $VNDA

Inhibikase Therapeutics Inc · Vanda Pharmaceuticals Inc

IKT

Inhibikase Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Compare $IKT vs $VNDA

Comparing Inhibikase Therapeutics Inc and Vanda Pharmaceuticals Inc

IKTInhibikase Therapeutics Inc

VNDAVanda Pharmaceuticals Inc

IKTInhibikase Therapeutics Inc

Market cap

$309M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.0%

52W performance

18.7%

FCF yield

-13.8%

VNDAVanda Pharmaceuticals Inc

Market cap

$275M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.89x

Rev growth (TTM)

6.0%

YTD performance

-44.6%

52W performance

-16.3%

FCF yield

-55.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IKT

VNDA

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Market Cap

IKT$309M

VNDA$275M

Enterprise Value

IKT$278M

VNDA$226M

Price

IKT$1.97

VNDA$4.57

P/E Ratio

IKTN/A

VNDAN/A

P/S Ratio

IKT872.10x

VNDA1.27x

EV/Sales

IKT774.58x

VNDA1.05x

EV/EBITDA

IKT0.00x

VNDA183.49x

P/B Ratio

IKT1.82x

VNDA1.29x

P/FCF Ratio

IKTN/A

VNDAN/A

EV/FCF

IKT-6.53x

VNDA-1.48x

PEG Ratio

IKTN/A

VNDAN/A

Forward P/E (NTM)

IKTN/A

VNDAN/A

Forward P/S (NTM)

IKTN/A

VNDA0.89x

Revenue (TTM)

IKT$0

VNDA$216M

Revenue Growth (YoY)

IKTN/A

VNDA6.0%

Forward Rev Growth

IKT0.0%

VNDA35.6%

Gross Margin (TTM)

IKT0.0%

VNDA93.7%

Operating Margin (TTM)

IKT0.0%

VNDA0.0%

EBITDA Margin (TTM)

IKT0.0%

VNDA-82.1%

Net Margin (TTM)

IKT0.0%

VNDA-127.4%

FCF Margin (TTM)

IKTN/A

VNDA-70.9%

Net Income (TTM)

IKT$-44M

VNDA$-275M

FCF (TTM)

IKT$-43M

VNDA$-153M

EPS (TTM)

IKT-$0.25

VNDA-$4.56

ROE (TTM)

IKT-4690.0%

VNDA-8495.0%

ROA (TTM)

IKT-4348.0%

VNDA-5679.0%

ROIC (TTM)

IKT-4690.0%

VNDA-8320.0%

Cash

IKT$31M

VNDA$56M

Debt

IKT$0

VNDA$7M

Net Cash/Debt

IKT$31M

VNDA$49M

Current Ratio (TTM)

IKT15.82x

VNDA1.61x

Quick Ratio (TTM)

IKT15.50x

VNDA1.40x

Debt/Equity (TTM)

IKT0.00x

VNDA0.03x

Debt/Assets (TTM)

IKT0.0%

VNDA0.0%

Interest Coverage (TTM)

IKTN/A

VNDAN/A

Net Debt/EBITDA (TTM)

IKT0.00x

VNDA0.00x

Beta

IKT0.92

VNDA0.69

52W Performance

IKT18.7%

VNDA-16.3%

YTD Performance

IKT1.0%

VNDA-44.6%

% from 52W High

IKT-24.5%

VNDA-54.0%

% from 52W Low

IKT48.1%

VNDA7.0%

Asset Turnover (TTM)

IKT0.01x

VNDA0.45x

FCF Yield (TTM)

IKT-13.8%

VNDA-55.7%

Earnings Yield (TTM)

IKT-14.3%

VNDA-100.0%

Dividend Yield (TTM)

IKTN/A

VNDAN/A

Rule of 40

IKT0.0

VNDA-64.9

EV/GP/RG

IKTN/A

VNDA0.01

Ticker research

View IKT research View VNDA research

Metric	IKT Inhibikase Therapeutics Inc	VNDA Vanda Pharmaceuticals Inc
Market & Valuation
Market Cap	$309M	$275M
Enterprise Value	$278M	$226M
Price	$1.97	$4.57
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	1.27x
EV/Sales	774.58x	1.05x
EV/EBITDA	0.00x	183.49x
P/B Ratio	1.82x	1.29x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-1.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.89x
Revenue & Growth
Revenue (TTM)	$0	$216M
Revenue Growth (YoY)	N/A	6.0%
Forward Rev Growth	0.0%	35.6%
Profitability
Gross Margin (TTM)	0.0%	93.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-82.1%
Net Margin (TTM)	0.0%	-127.4%
FCF Margin (TTM)	N/A	-70.9%
Net Income (TTM)	$-44M	$-275M
FCF (TTM)	$-43M	$-153M
EPS (TTM)	-$0.25	-$4.56
ROE (TTM)	-4690.0%	-8495.0%
ROA (TTM)	-4348.0%	-5679.0%
ROIC (TTM)	-4690.0%	-8320.0%
Financial Health
Cash	$31M	$56M
Debt	$0	$7M
Net Cash/Debt	$31M	$49M
Current Ratio (TTM)	15.82x	1.61x
Quick Ratio (TTM)	15.50x	1.40x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.69
52W Performance	18.7%	-16.3%
YTD Performance	1.0%	-44.6%
% from 52W High	-24.5%	-54.0%
% from 52W Low	48.1%	7.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.45x
FCF Yield (TTM)	-13.8%	-55.7%
Earnings Yield (TTM)	-14.3%	-100.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-64.9
EV/GP/RG	N/A	0.01
Ticker research	View IKT research	View VNDA research

Valuation

P/S Ratio

VNDA

1.27x

IKT

872.10x

EV/FCF

IKT

-6.53x

VNDA

-1.48x

Growth & revenue

Revenue Growth TTM

VNDA

6.0%

Forward Revenue Growth

VNDA

35.6%

IKT

0.0%

Profitability & performance

Gross Margin

VNDA

93.7%

IKT

0.0%

ROE

IKT

-4690.0%

VNDA

-8495.0%

FCF Yield %

IKT

-13.8%

VNDA

-55.7%

52-Week Performance

IKT

18.7%

VNDA

-16.3%

Detailed metrics comparison

IKT

Inhibikase Therapeutics Inc

VNDA

Vanda Pharmaceuticals Inc

Market Cap

IKT$309M

VNDA$275M

Enterprise Value

IKT$278M

VNDA$226M

Price

IKT$1.97

VNDA$4.57

P/E Ratio

IKTN/A

VNDAN/A

P/S Ratio

IKT872.10x

VNDA1.27x

EV/Sales

IKT774.58x

VNDA1.05x

EV/EBITDA

IKT0.00x

VNDA183.49x

P/B Ratio

IKT1.82x

VNDA1.29x

P/FCF Ratio

IKTN/A

VNDAN/A

EV/FCF

IKT-6.53x

VNDA-1.48x

PEG Ratio

IKTN/A

VNDAN/A

Forward P/E (NTM)

IKTN/A

VNDAN/A

Forward P/S (NTM)

IKTN/A

VNDA0.89x

Revenue (TTM)

IKT$0

VNDA$216M

Revenue Growth (YoY)

IKTN/A

VNDA6.0%

Forward Rev Growth

IKT0.0%

VNDA35.6%

Gross Margin (TTM)

IKT0.0%

VNDA93.7%

Operating Margin (TTM)

IKT0.0%

VNDA0.0%

EBITDA Margin (TTM)

IKT0.0%

VNDA-82.1%

Net Margin (TTM)

IKT0.0%

VNDA-127.4%

FCF Margin (TTM)

IKTN/A

VNDA-70.9%

Net Income (TTM)

IKT$-44M

VNDA$-275M

FCF (TTM)

IKT$-43M

VNDA$-153M

EPS (TTM)

IKT-$0.25

VNDA-$4.56

ROE (TTM)

IKT-4690.0%

VNDA-8495.0%

ROA (TTM)

IKT-4348.0%

VNDA-5679.0%

ROIC (TTM)

IKT-4690.0%

VNDA-8320.0%

Cash

IKT$31M

VNDA$56M

Debt

IKT$0

VNDA$7M

Net Cash/Debt

IKT$31M

VNDA$49M

Current Ratio (TTM)

IKT15.82x

VNDA1.61x

Quick Ratio (TTM)

IKT15.50x

VNDA1.40x

Debt/Equity (TTM)

IKT0.00x

VNDA0.03x

Debt/Assets (TTM)

IKT0.0%

VNDA0.0%

Interest Coverage (TTM)

IKTN/A

VNDAN/A

Net Debt/EBITDA (TTM)

IKT0.00x

VNDA0.00x

Beta

IKT0.92

VNDA0.69

52W Performance

IKT18.7%

VNDA-16.3%

YTD Performance

IKT1.0%

VNDA-44.6%

% from 52W High

IKT-24.5%

VNDA-54.0%

% from 52W Low

IKT48.1%

VNDA7.0%

Asset Turnover (TTM)

IKT0.01x

VNDA0.45x

FCF Yield (TTM)

IKT-13.8%

VNDA-55.7%

Earnings Yield (TTM)

IKT-14.3%

VNDA-100.0%

Dividend Yield (TTM)

IKTN/A

VNDAN/A

Rule of 40

IKT0.0

VNDA-64.9

EV/GP/RG

IKTN/A

VNDA0.01

Ticker research

View IKT research View VNDA research

Metric	IKT Inhibikase Therapeutics Inc	VNDA Vanda Pharmaceuticals Inc
Market & Valuation
Market Cap	$309M	$275M
Enterprise Value	$278M	$226M
Price	$1.97	$4.57
P/E Ratio	N/A	N/A
P/S Ratio	872.10x	1.27x
EV/Sales	774.58x	1.05x
EV/EBITDA	0.00x	183.49x
P/B Ratio	1.82x	1.29x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.53x	-1.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.89x
Revenue & Growth
Revenue (TTM)	$0	$216M
Revenue Growth (YoY)	N/A	6.0%
Forward Rev Growth	0.0%	35.6%
Profitability
Gross Margin (TTM)	0.0%	93.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-82.1%
Net Margin (TTM)	0.0%	-127.4%
FCF Margin (TTM)	N/A	-70.9%
Net Income (TTM)	$-44M	$-275M
FCF (TTM)	$-43M	$-153M
EPS (TTM)	-$0.25	-$4.56
ROE (TTM)	-4690.0%	-8495.0%
ROA (TTM)	-4348.0%	-5679.0%
ROIC (TTM)	-4690.0%	-8320.0%
Financial Health
Cash	$31M	$56M
Debt	$0	$7M
Net Cash/Debt	$31M	$49M
Current Ratio (TTM)	15.82x	1.61x
Quick Ratio (TTM)	15.50x	1.40x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	0.69
52W Performance	18.7%	-16.3%
YTD Performance	1.0%	-44.6%
% from 52W High	-24.5%	-54.0%
% from 52W Low	48.1%	7.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.45x
FCF Yield (TTM)	-13.8%	-55.7%
Earnings Yield (TTM)	-14.3%	-100.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-64.9
EV/GP/RG	N/A	0.01
Ticker research	View IKT research	View VNDA research